Shingrix vaccine study probes skin immunity in young and old
NCT ID NCT04403139
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the Shingrix vaccine, which protects against shingles, affects immune cells in the skin and blood. Researchers will give the vaccine to 50 healthy adults in two age groups: 30-40 years old and 70 years or older. They will measure specific antibodies and T-cells to understand how the vaccine triggers long-lasting immunity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Shingrix (recombinant zoster vaccine)
- What this could lead to
- If successful, this study could help explain how the Shingrix vaccine protects against shingles, potentially improving future vaccines.
- What could go wrong
- This is a small, early-phase study with only 50 participants, so results may not apply to everyone. It measures immune markers, not actual disease prevention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA ZOSTER VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Washington Virology Research Clinic
Seattle, Washington, 98104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.